Showing posts with label chemotherapy. Show all posts
Showing posts with label chemotherapy. Show all posts

Tuesday, December 28, 2010

Seven Lots of Dexamethasone Injection Recalled

Robert Lowes

December 27, 2010 — American Regent is voluntarily recalling 7 lots of dexamethasone sodium phosphate injection (USP 4 mg/mL, 30 mL multiple-dose vials) because some vials either contain particulates or have the potential to do so before their expiration dates, the US Food and Drug Administration (FDA) announced today.

A corticosteroid, dexamethasone is used to treat a wide variety of conditions such as severe allergic reactions, arthritis, blood diseases, certain cancers, and breathing disorders. Clinicians also use it to test for Cushing's syndrome and prevent nausea and vomiting in chemotherapy patients. The injectable form of the drug is used when a similar drug cannot be taken orally, or when a patient in a medical emergency needs a rapid response.

The recall pertains to the lots of the product listed in the table.

Table. Recalled Lots

Lot Expiration Date (Month/Year)
8811 12/2010
9093 02/2011
9195 03/2011
9296 04/2011
9419 06/2011
9505 07/2011
9649 09/2011

American Regent issued the recall on December 20. Hospitals, infusion centers, clinics, and other healthcare facilities should not use any of the recalled lots but should instead quarantine them for return to the company. Anyone with questions about the return process or any other issue can call American Regent at 1-800-645-1706.

The company reminds clinicians that as a matter of standard practice, they should visually inspect parenteral drugs for particulate matter and discoloration before administration, whenever the solution or container permits.

More information about today's announcement is available on the FDA Web site.

To report adverse events related to injectable dexamethasone, contact MedWatch, the FDA's safety information and adverse event reporting program, by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at http://www.fda.gov/medwatch, or by mail to MedWatch, FDA, 5600 Fishers Lane, Rockville, Maryland 20852-9787.

From http://www.medscape.com/viewarticle/734851

Monday, October 12, 2009

Cushing’s: the worst case scenario

Ami found this older abstract from last year.  Please, if you think you have Cushing's - or any serious disease - advocate for yourself before it's too late.  Over the years, too many Cushies have died. It's time to take charge of your life, the only one you will ever have...

Endocrine Abstracts (2008) 15 S58

Cushing’s: the worst case scenario

Viv Thornton-Jones

Churchill Hospital, Oxford, UK.


We present the case of a 40-year-old female who was referred to our Department in 1993, for further management following the diagnosis of Cushing’s disease. She proceeded to a transsphenoidal adenenomatectomy (TSA) which resulted in a biochemical cure.

In 1998 she presented with recurrence of Cushing’s Disease, which was managed by a 2nd TSA followed by external beam irradiation.

Bilateral adrenalectomy followed a year later, due to the inability to control her disease.

In 2001 she presented with Nelson’s Syndrome managed by a 3rd TSA followed this time with Gamma Knife surgery.

In 2004 she presented with manifestations consistent with recurrence of Nelson’s Syndrome and proceeded to a 4th TSA. Despite the risk of blindness, the patient agreed to a second course of Gamma Knife treatment for the possibility of tumour control.

Over the next 2 years her clinical picture deteriorated, resulting in a right partial ptosis and a sixth nerve palsy.

She was referred to an Oncologist who offered her Chemotherapy, but she refused treatment.

The patient was then in the care of the Palliative Care Team and she died peacefully at home in 2006.


Endocrine Abstracts (2008) 15 S58

From http://www.endocrine-abstracts.org/ea/0015/ea0015S58.htm

Sunday, July 12, 2009

Cushing's Syndrome

Medical Codes

ICD-9-CM:
255, 255.0

255 -
Disorders of Adrenal Glands

255.0 -
Disorders of Adrenal Glands, Cushings Syndrome; Adrenal Hyperplasia Due to Excess ACTH Cushings Syndrome NOS, Iatrogenic, Idiopathic, Pituitary-Dependent, Ectopic ACTH Syndrome, Iatrogenic Syndrome of Excess Cortisol, Overproduction of Cortisol

Definition

Cushing's syndrome is a condition caused by excess corticosteroids in an individual's body. These steroids can be produced by the body itself or can result from high doses of medical steroids being administered to the individual. Cushing's syndrome is characterized by a large, round face and a thick torso with comparatively thin arms and legs. Muscle weakness, depression, hallucinations, thin skin that bruises easily and heals slowly, and purple streaks on the abdomen are also common signs and symptoms of this condition.


The adrenal glands located on top of the kidneys produce cortisol. Under normal conditions, the release of cortisol is controlled by the pituitary gland and the hypothalamus in the brain. The hypothalamus sends a hormone (corticotropin-releasing hormone or CRH) to the pituitary gland. CRH causes the pituitary gland to secrete a hormone called ACTH (adrenocorticotropic hormone). ACTH is the signal for the adrenal gland to produce cortisol.


A common cause of Cushing's syndrome is the administration of glucocorticoid drugs (such as prednisone) or ACTH for various medical reasons. This is called exogenous Cushing's syndrome. Individuals with any disease requiring prolonged use of corticosteroid medications are at increased risk of developing Cushing's syndrome. Examples of some medical conditions that are often treated with glucocorticoids or ACTH and may increase one's risk of developing Cushing's syndrome include rheumatoid arthritis, lupus, asthma, or other chronic inflammatory diseases.


When a tumor (adenoma) of the pituitary gland produces excessive amounts of ACTH, there is a subsequent release of excess cortisol by the adrenal glands. This condition is called Cushing's disease (hypercortisolism), and it accounts for about 70% of the naturally occurring (endogenous) cases of Cushing's syndrome. Another 15% of the naturally occurring cases of Cushing's syndrome are caused by release of cortisol from noncancerous (benign) or cancerous (malignant) tumors of the adrenal gland (adrenal adenoma and adrenal carcinoma). The remaining 15% of cases are caused by the production of ACTH by a tumor (either benign or malignant) located elsewhere in the body (ectopic ACTH syndrome) (Adler).

 

Risk: Cushing's syndrome most commonly affects adults between the ages of 20 and 50, although it can strike at any age. Although Cushing's syndrome is not inherited, some people have an inherited predisposition to tumors of the hormone-secreting glands. This predisposition places these individuals at a higher risk for Cushing's syndrome than the general population.


Cushing's disease more commonly affects women of reproductive age, but it can occur in men and women at any age (Kirk). Women are five times more likely than men to have Cushing's syndrome caused by a pituitary or an adrenal tumor (Adler).


Ectopic ACTH syndrome is caused by lung tumors (usually carcinoid) in 50% of cases. Other ACTH-producing tumors include thymomas, pancreatic islet cell carcinomas, and medullary carcinomas of the thyroid. Ectopic ACTH syndrome affects men more often than women because lung cancer occurs more frequently among men (Adler).

 

Incidence and Prevalence: Cushing's syndrome is relatively rare, affecting about 13 of every million individuals each year (Adler).

Diagnosis

History: Frequent complaints include weight gain, fatigue, muscle weakness (especially of the upper arms and thighs), easy bruising, poor wound healing, thinning scalp hair, abnormal growth of body hair and purple streaking (striae) of the breasts, buttocks, lower abdomen and thighs. Individuals may also complain of excessive thirst and frequent urination. Psychiatric symptoms include mood swings, depression, and personality changes (steroid psychosis). Women may notice changes in the menstrual flow (oligomenorrhea or amenorrhea), and men may complain of decreased sex drive (libido) and inability to achieve or maintain an erection (erectile dysfunction). Often, individuals will report that routine bending, lifting, or rising from a chair has become difficult or painful.

 

Physical exam: High blood pressure (hypertension) is seen in over 80% of cases. There are some striking physical changes in Cushing's syndrome. The face is round and unusually red. Acne may be present. Obesity is common; 50% of individuals gain weight in the abdomen and buttocks while the arms and legs are normal. Fat pads appear over the collarbones and upper spine.

 

Tests: If it has been determined from the history and physical exam that the individual is not showing the signs of Cushing's syndrome from prescribed medications, further testing is carried out at two levels. First, it must be determined whether the individual has elevated levels of cortisol. A 24-hour urine collection is taken, and the amount of cortisol in the urine is measured. The cortisol level will be elevated in individuals with Cushing's syndrome. Another test is the overnight dexamethasone suppression test. Dexamethasone is a steroid medication that suppresses ACTH release and lowers the early morning levels of blood cortisol in normal individuals but has no effect in individuals with Cushing's syndrome. A newer means to detect Cushing's syndrome uses a combination of the CRH stimulation test with the dexamethasone suppression test. Cortisol levels exceeding 1.4 µg per L would be diagnostic for Cushing's syndrome. This method is reported to have a very high rate of diagnostic accuracy.


Once the diagnosis of Cushing's syndrome is established, a second level of testing is carried out to determine the cause of the disease: a tumor of the pituitary gland or adrenal glands or a tumor that stimulates the adrenal glands through ectopic ACTH secretion. A test called the CRH stimulation test is often performed to help distinguish individuals with Cushing's syndrome due to pituitary adenomas from those with ectopic ACTH syndrome or cortisol-secreting adrenal tumors.

In the CRH stimulation test, individuals are given an injection of CRH. Those with a pituitary adenoma usually experience a rise in blood levels of ACTH and cortisol. This response is rarely seen in people with ectopic ACTH syndrome and practically never in those with cortisol-secreting adrenal tumors.


Routine chest x-rays are done, along with CT of the chest in suspected cases of ectopic ACTH production. A CT of the adrenal glands can show an adrenal tumor, or in the case of a pituitary tumor that stimulates both glands, enlarged adrenal glands. MRI of the pituitary gland is done in cases of suspected pituitary tumors. Pituitary adenomas are only seen on 50% of MRI tests, so it is important that the biochemical testing is thorough before surgery (Kirk).


Blood tests may also show high levels of sugar (hyperglycemia), fat (hyperlipidemia), or potassium (hyperkalemia) and abnormal numbers of certain white blood cells (neutrophilia, lymphopenia).

Treatment

If the condition is caused by overmedication, it is treated by reducing the dosage of glucocorticoids or changing the medication. When the underlying cause is a benign or malignant tumor of the adrenal gland, the tumor must be surgically removed.


The treatment of choice for tumors of the pituitary gland is surgical removal. Irradiation of the pituitary gland has a lower success rate and a higher rate of complications, and notable improvement may not be noted for a year or more. Hormone replacement therapy usually follows surgery and, in some cases, must be continued for life.


Medical treatment (chemotherapy) is usually not recommended as the primary treatment for Cushing's syndrome but is an alternative if surgery is not possible and may be used with radiation treatments to hasten better results. If the cause of Cushing's syndrome is ectopic ACTH, treatment is directed at the underlying disease.

 

Prognosis

Before the introduction of effective therapy approximately 50% of patients with untreated Cushing's syndrome died within 5 years. Now with appropriate medical intervention, the outcome of endogenous Cushing's is generally good. Cushing's secondary to ACTH-producing tumors of the adrenal gland are often treated by surgical removal of the adrenal gland, which has a 100% cure rate. However, Cushing's secondary to ACTH-producing tumors of the lung generally has a poor outcome (Stewart 522).

 

Complications

Cushing's syndrome is complicated by high blood pressure, diabetes, increased susceptibility to infections, emotional disturbances, and metastasis of cancerous tumors. The bones become fragile (osteoporosis), and compression fractures of the spine are common.

 

Return to Work (Restrictions / Accommodations)

No restrictions or accommodations should be necessary once the individual returns to work.

 

Failure to Recover

If an individual fails to recover within the expected maximum duration period, the reader may wish to consider the following questions to better understand the specifics of an individual's medical case.

 

Regarding diagnosis:

  • On exam, are symptoms present such as hypertension, red, round face, acne, and weight gain in the abdomen and buttocks or fat pads over the collarbones and upper spine? Does individual have a thick torso with comparatively thin arms and legs?
  • Does individual also have muscle weakness, thin skin that bruises easily and heals slowly, and purple streaks on the abdomen, breasts, buttocks and thighs?
  • Does individual have a pituitary tumor, adrenal tumor, small cell lung cancer, thymomas, pancreatic islet cell carcinomas, or medullary carcinomas of the thyroid?
  • Is individual being treated with glucocorticoid drugs for another condition?
  • Does individual have a family history of tumors of the hormone-secreting glands?
  • Does individual complain of weight gain, fatigue, thinning scalp hair, excessive body hair, excessive thirst, and frequent urination?
  • Does individual have mood swings, depression, hallucinations, and personality changes?
  • Does individual have oligomenorrhea or amenorrhea? Decreased libido? Impotence? Does individual report that routine bending, lifting, or rising from a chair is difficult or painful?
  • Were cortisol levels tested? Was individual tested for the presence of cortisol-secreting tumors?
  • Was an overnight dexamethasone suppression test done? Was a combination CRH stimulation and dexamethasone suppression test done to confirm the diagnosis? CT or MRI? Comprehensive blood testing? Was inferior petrosal sinus sampling done?
  • Were conditions with similar symptoms ruled out?

 

Regarding treatment:

  • Is the condition caused by overmedication? Is the dosage of glucocorticoids reduced or the medication changed?
  • Is the condition caused by a tumor? Was it surgically removed? Is individual on hormone replacement therapy?

 

Regarding prognosis:

  • Does individual have any conditions that may affect ability to recover?
  • Have any complications developed, such as high blood pressure, diabetes, infections, emotional disturbances, metastasis of tumors, osteoporosis, and compression fractures of the spine?

 

Cited References

Adler, Gail. "Cushing Syndrome." eMedicine. Eds. William Chiang, et al. 17 Aug. 2004. Medscape. 28 Sep. 2004 http://emedicine.com/emerg/topic117.htm.

 

Kirk, Lawrence F., et al. "Cushing's Disease: Clinical Manifestations and Diagnostic Evaluation." American Academy of Family Physicians. 28 Sep. 2004 http://www.aafp.org/afp/20000901/1119.html.

 

Stewart, Paul M. "Therapeutic Corticosteroids." Williams Textbook of Endocrinology. Eds. R. H. Williams and Reed P. Larsen. 10th ed. Philadelphia: Elsevier, Inc., 2003. 508-525. MD Consult. Elsevier, Inc. 28 Sep. 2004 http://home.mdconsult.com.

 

From http://www.mdguidelines.com/cushings-syndrome

Saturday, July 4, 2009

Adrenal Testing and Treatment

In the first two newsletters in this series, we discussed the following:
• The endocrine system and how it is composed of glands throughout the body that  release hormones (chemical messengers) into the bloodstream or the fluid surrounding cells. These hormones activate receptors and either alter the cell's existing proteins or instruct the cell in the building of new proteins that create actions in the body.

• The importance of the hypothalamus and the pituitary gland and how these two glands control the two adrenal glands--the HPA axis as it is called, and control the thyroid; 

• Each adrenal gland has two parts, the adrenal cortex and the adrenal medulla and the purpose of each;

• The symptoms of adrenal problems and how many of them are similar to symptoms created by problems in the thyroid and other endocrine glands;

• The primary purpose of the adrenal glands, and the entire endocrine system, is to keep the body in a balanced condition called homeostasis;

• The purpose of cortisol and the problems created when cortisol levels are too high or too low;

• How the adrenals can create hypoglycemia, where blood sugar levels are lower than normal;

• How the adrenals affect fatigue, insomnia and obesity;

• How the adrenals affect proper hydration of the body.


Here are links to the first two articles in the series. (http://media.novusdetox.com/dependence.php?include=139775, http://media.novusdetox.com/dependence.php?include=139840)


   In this newsletter we will look at the tests used to determine adrenal problems and the most common treatments.


TESTS
   If you go to most doctors and say that you are suffering from insomnia, fatigue, hypoglycemia, weight gain and other symptoms of adrenal problems and ask for an adrenal test, most doctors will likely tell you that you need to just take this or that pill and go on a diet.  This is always true of Radio Medicine Doctors because they just want to turn up the volume and drown out the symptoms and not treat the cause.
   If you persist and demand that they test your adrenals, then they likely will do tests to determine if you have Addison's disease or Cushing's syndrome—diseases where you either have the lowest or highest amounts of cortisol. 
   First, we will look at the worst cases of adrenal problems and then the more common adrenal problems that affect the majority of us to a greater or lesser extent.


ADDISON'S DISEASE
   Addison's disease occurs when the adrenal glands do not produce enough cortisol and, in some cases, aldosterone. This disease is also called adrenal insufficiency, hypoadrenia (“hypo”=low and “ism” =condition of) or hypocortisolism.
According to the National Institute of Health:
• Addison's disease affects about 1 in 100,000 people;

• Adrenal insufficiency occurs when at least 90 percent of the adrenal cortex has been destroyed and no cortisol is being produced.


ADDISON'S DISEASE TESTS
   Two of the common tests used to diagnose Addison's disease are:
• ACTH Stimulation Test - where ACTH is released by the pituitary gland to signal the adrenals to produce more cortisol.  The ACTH Test usually measures the levels of  blood cortisol, urine cortisol before and after a synthetic form of ACTH is given by injection.  If the adrenals are functioning properly, there is an increase in blood and urine cortisol levels and the amount of the increase tells doctors about the extent of the adrenal problem.
• CRH Stimulation Test - if the ACTH test is abnormal, a CRH (cortisol releasing hormone from the hypothalamus) stimulation test is used to determine the cause of adrenal insufficiency.  Synthetic CRH is injected intravenously and blood cortisol is measured before and 30, 60, 90, and 120 minutes after the injection. If there is no ACTH response, this indicates the problem may be the pituitary gland.  If there is a delayed ACTH response, the hypothalamus may be the cause.


ADDISON'S DISEASE TREATMENT
   Treatment of Addison's disease requires replacement of the missing cortisol or replacement of the missing aldosterone. 


CUSHING’S SYNDROME
   Cushing’s syndrome or hypercortisolism (“hyper”=high and “ism” =condition of) is diagnosed when there is a high level of cortisol for a long period of time.   According to the National Institute of Health, Cushing’s syndrome is relatively rare and most commonly affects:
• Adults aged 20 to 50;
• People who are obese and have type 2 diabetes.
   Because of the dangerous effects of elevated cortisol levels, this is why people who take prednisone (a synthetic form of cortisone that is used in the treatment of rheumatoid arthritis and other inflammatory diseases) or any other form of cortisol should carefully monitor their cortisol levels. 


CUSHING’S SYNDROME TESTS
   Some of the common tests used to diagnose Cushing’s syndrome are:
• 24-hour urinary free cortisol test where urine is collected over a 24 hour period and tested for cortisol;

• Measurement of midnight plasma cortisol where blood tests to show the level of cortisol at night (when it should be lower at midnight)

• Late-night salivary cortisol where a saliva test is used to determine the level of cortisol at night;

• Giving high or low doses of synthetic cortisol and then checking the urine to see  if there is a drop in blood and urine cortisol levels;

• CRH stimulation test described above.

Cushing’s Syndrome Treatment

   While the treatment will depend on the cause for the high cortisol levels, some of the traditional options are:
• Surgery;
• Radiation
• Chemotherapy;
• Cortisol-inhibiting drugs.


ADRENAL FATIGUE
   As we have learned, your adrenals can be causing problems but you do not have Addison's disease or Cushing's syndrome.  Therefore, if you don't have either disease, most doctors don't really address adrenal fatigue—where your adrenals are just not working properly. What if you are experiencing some or all of these symptoms:
• Fatigue
• Have trouble sleeping
• Anxiety
• Sudden weight gain
• Libido is lessened
• Salt cravings


THE SOLUTION--ALTERNATIVE MEDICINE DOCTORS
   As we have advised in previous newsletters, it is recommended that you find a doctor who will actually spend the time to find out the physiological cause of your symptoms and treat them.  Since the symptoms listed above can be caused by problems with other glands, the doctor will likely have you do a complete set of tests on your most important hormones. 


SALIVA CORTISOL TEST
   This test measures the cortisol levels at least four times during the day, because cortisol levels are supposed to be highest in the morning and start declining until about midnight and then start rising again.  The person uses a small tube to collect the saliva, marks the time and then at set times during the rest of the day and evening the person again spits in a new tube and marks the time.  If the person is feeling more fatigued at certain times of the day, then some doctors will also have the saliva test done when they feel fatigued.  The saliva samples are then sent to a lab and the cortisol levels for the testing period are shown. 
   Using this information, the doctor can then advise you as to whether you have adrenal fatigue.


TREATMENT OF ADRENAL FATIGUE
   While many doctors are quick to prescribe drugs to address any type of adrenal problem, most alternative medicine doctors will try to use a non-pharmaceutical approach.  Here are some of the things that are outlined in Adrenal Fatigue by Dr. James Wilson:
• Do relaxation exercises
• Adjust your sleeping hours
• Physical exercise
• Change your eating times and habits
   ◦ 40% raw or lightly cooked vegetables
   ◦ 30% whole grains
   ◦ 15% beans, seeds and nuts
   ◦ 10% animal foods
   ◦ 5% fruits
• Supplements
   ◦ Vitamin C
   ◦ Magnesium (particularly if you crave chocolate)
   ◦ Vitamin E
   ◦ B vitamins
   ◦ Calcium
   ◦ Fiber
   ◦ Certain herbs


DR. BRENT AGIN'S TREATMENT FOR ADRENAL FATIGUE
   Dr. Agin is  Novus Medical Detox Center's medical director.   In addition to advising on diet changes and on many of the things recommended by Dr. Wilson, Dr. Agin has developed injectable (intra-muscular) vitamins, minerals and herbs that will help provide the support that the adrenals need to recover.  Dr. Agin believes that injecting these supplements directly will ensure that more is actually converted and used by the body.  The following are the supplements that Dr. Agin's research has indicated are needed to help the adrenals recover:
Vitamin C – 2,000-4,000 mg per day (supports the adrenals and improves immune function)
B-Complex - which includes the following:
• B5 - (Pantothenic acid) 1,000-1,500 mg per day
• B6 -  50-100 mg daily
• B3 - 75-125 mg daily
• B12 - 200-400 mcg daily
Minerals:
• Chromium
Herbal support:
• Licorice Root   (not the candy!)- This is well known for supporting the adrenals. It has calming properties along with an ability to increase endurance and energy. It can be taken as a tea, capsule or liquid(in rare cases if large amounts are ingested it can increase the blood pressure).

• Ashwaganda Root- This is considered an adaptogen.  An adaptogen is an herb that  will help normalize cortisol levels. If there is too much cortisol, it will lower the level, if the level is too low, it will help to increase it.

• Siberian Ginseng- This root helps to uphold and revive adrenal function along with increasing the body’s resistance to stress and normalizing the metabolism. It has antidepressant properties and promotes calmness and a sense of well being.  It has  been shown to stimulate antibodies to help fight off viruses and harmful bacteria. It also aids in the absorption of B vitamins.  (This root usually helps to normalize blood pressure, but if someone has very high blood pressure, then it would still be best to avoid it.)

• Ginkgo- When the adrenals are under a lot of stress, there is an increase in the number of free radicals and if not neutralized, then there is increased risk to the immune system. Ginkgo is a powerful antioxidant along with other supplements that are believed to help counteract the free radicals.
   In some cases, Dr. Agin will prescribe additional injectable supplements.  The shots are painless and easy to give to yourself.  If you are interested in more data about Dr. Agin's injectable products, please email us.

CONCLUSION

   At Novus Medical Detox Center, we are very proud that we help people who have become dependent or addicted to substances like OxyContin, methadone, Vicodin, Percocet, heroin, and psychoactive drugs like Xanax and Zoloft and to people who have become addicted to alcohol. 
   Please call us if we can help someone that you know.
NOTE: This information is provided for general educational purposes only and is not intended to constitute (i) medical advice or counseling, (ii) the practice of medicine, health care diagnosis or treatment, or (iii) the creation of a physician patient or clinical relationship.  If you have or suspect that you have a medical problem or that this information may be useful to you or others, please consult with your health care provider before applying any information from our articles to your personal situation or to the personal situation of others.
FAIR USE NOTICE: This may contain copyrighted (C) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C.
Section 107 of the US Copyright Law. This material is distributed without profit.

Technorati Tags: adrenal glands, endocrine system, fatigue, addison's disease, cushing's syndrome, cortisol,

From http://media.novusdetox.com/dependence.php?include=139924

Friday, June 19, 2009

His kidney cancer symptoms were just like mine!

The only difference was my pain was in the front.  I have never in my life had such excruciating pain.  Mine came across suddenly.  Pain in afternoon, diagnosed with cancer in ER three hours later.  No pesky going from doctor to doctor, testing and more testing with this cancer.  Bang - instant diagnosis.

More info in this old post

I loved this quote at the end and need to remember it and quote it each day: “This is living with cancer. But you’re living.” 

My version will be “This is living with post-Cushing's, panhypopituitarisim, low growth hormone, low adrenal function and cancer. But you’re living.”

From http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/1131

Reining in Renal Cancer

BY KAREN PATTERSON

As new therapies stack up, controlling advanced kidney cancer is becoming a reality.

 

Tattooed in Chinese lettering over the former location of Marc Benner’s right kidney are the words “Kidney Cancer Survivor”—emblems of his year-and-a-half-long journey battling stage 4 renal cell carcinoma.

Benner, of Jackson, New Jersey, was 42 in 2007 when he began feeling excruciating pain in his back and noticed blood in his urine. “Like most guys, back then you couldn’t get me to the hospital,” he says. “I thought I was just passing a stone, to be honest.” In December that year, surgeons at Thomas Jefferson University Hospital in Philadelphia removed his kidney using minimally invasive robotic surgery. At the same time they excised a lung mass. He was back at work 10 days later.

But his battle was only beginning. His first set of scans in early 2008 showed masses in his liver and lung. That’s when his doctors prescribed Sutent (sunitinib), one of several relatively new drugs for advanced kidney cancer. Benner took Sutent for about a year, in cycles where he was on the drug for four weeks and off for two. Although he still has nodules in his lung—and a tumor just above his hip—the spots on his liver have disappeared. “I think it helped buy me time,” he says of the drug. And the self-described “gym rat”  has been lifting more weight than ever in his workouts.

When his cancer progressed on Sutent, he switched to Nexavar (sorafenib). “I’ve heard a lot of good things about Nexavar,” he says, three weeks after beginning the drug. Ultimately, he hopes that this drug, too, will buy him time until other treatments are available. “There’s some new stuff out there that might work better,” he says.

Benner is typical not just because his cancer is a type known as clear cell, which accounts for the vast majority of the almost 55,000 renal cancers diagnosed in the United States yearly, but also in his mix of hope for the future and anticipation of what’s coming next through the pharmaceutical pipeline.

Robert Figlin, MD, interim director of City of Hope Comprehensive Cancer Center in Duarte, California, and director of the center’s kidney cancer program, says that more treatments are available for metastatic renal cell carcinoma (RCC) than ever. In addition to the current arsenal of Sutent, Nexavar, and Torisel (temsirolimus), and the newly approved Afinitor (everolimus), all green-lighted by the Food and Drug Administration since December 2005, one additional product is likely to receive approval for kidney cancer this year—Avastin (bevacizumab). While they don’t promise a cure, collectively the five drugs have the potential to extend patients’ lives considerably.

Before the new agents came on the market, “there was no progress and few options,” says Robert Motzer, MD, who oversees the clinical trials program for advanced kidney cancer at Memorial Sloan-Kettering Cancer Center in New York City. “Now it’s changed dramatically. … You can see it in the faces of the patients.”

“This is a waterfall time for patients,” adds Figlin, who is also chair of medical oncology and therapeutics research at City of Hope. “The challenges for both doctors and patients are now how to choose the proper drugs, in what sequence, and whether or not to use them in combination.”

These new, so-called targeted, drugs vary in their mechanism of action in the body. Sutent, Nexavar, and Avastin disrupt a process known as angiogenesis—the formation of blood vessels that feed tumors. In a phase III trial to demonstrate Avastin’s potential benefit, a combination of the drug and an older treatment, interferon, nearly doubled the window of time in which patients’ metastatic RCC failed to progress, compared with placebo plus interferon.

Torisel and Afinitor are in a class of drugs called mTOR inhibitors, which means they target a cell protein that is part of a biochemical pathway implicated in the growth of tumor cells as well as blood vessels. While phase III trials have shown, for instance, that Sutent versus interferon can more than double the time before progression for many advanced kidney cancers, the mTOR inhibitors might be able to extend that period further.

In addition, Torisel, which is given intravenously weekly, has been studied in the treatment of patients with poor prognosis RCC—“those with the most symptoms, most extensive disease, who would otherwise have a short survival,” says Motzer. “It was the first of the targeted agents to show a survival benefit in that very poor prognosis population.” That population, he adds, accounts for up to one-quarter of people who are first diagnosed with metastatic kidney cancer.

The eagerly anticipated approval of Afinitor occurred in late March. That drug is administered orally, and updated results from a phase III trial examining people whose cancers had progressed on Sutent, Nexavar, or both found that Afinitor delayed the cancer’s progression by a median period of almost five months, compared with just less than two months in patients receiving a placebo. Afinitor also compared favorably to the other drugs in terms of quality of life and safety profile, with mouth ulcers and anemia among the side effects.

“The sense we have is that if a cancer cell builds up resistance to one medicine with one mechanism of action, switching over to another mechanism is attractive,” Motzer says.

A Chronic Disease?

Figlin says evidence most strongly supports using the new agents in sequence, with the antiangiogenic agents first, followed by an mTOR inhibitor if the cancer progresses. “That’s not to say other drugs can’t be interwoven, but the data are not as robust.”

Research into combinations of the targeted agents has, meanwhile, been disappointing. “Our early studies showed there seemed to be more toxicity in the combinations,” Motzer says. “So I’m more firmly behind the sequential use of these agents.”

The new drugs also appear beneficial for the approximately 20 percent of RCC patients whose tumors are not clear-cell type. While the benefits might not be as dramatic, “these targeted agents should still be used,” Figlin says.

For advanced clear-cell RCC, the medicines have made a dramatic difference in physicians’ conversations with patients. Figlin says he can tell newly diagnosed patients and their families that there’s a high chance of benefit from the treatment, with the potential to improve symptoms and extend life. “Although they are not curative treatments, they can turn this disease into more of a chronic management disease,” he says. “We were not able to have that conversation just five years ago.”

Coming down the pipeline are other promising new agents currently being tested in large phase III trials. “We are already embarking on next-generation drugs,” Figlin says, including the angiogenesis inhibitors pazopanib and axitinib, which have a mechanism of action similar to Sutent and Nexavar. “Both of these may have more activity than our currently available drugs.” They might also have a better side effect profile, he says. “That’s what we’re looking for—better tolerance and more effectiveness.”

The AXIS trial, a phase III study still recruiting patients, will test how axitinib measures up to Nexavar as second-line treatment for metastatic RCC. Results of the study are expected in mid-2010. Also going head-to-head in a phase III study are pazopanib and Sutent in locally advanced or metastatic RCC.

Experts agree there’s room to improve the targeting of known biochemical pathways related to kidney cancer as well as other pathways that may be important but aren’t as clearly understood.

The Old Kid on the Block

Before the targeted agents arrived on the scene, treatments known as biological or immune therapies, which enlist the body’s immune system to fight the cancer, were the standard of care. One such treatment, interferon, available since the 1980s, prompted a response in just a fraction of patients, and most would later see their disease progress. Interferon, Figlin notes, is the agent to which the new drugs have been compared in many of the clinical trials, but it no longer has much of a role as a treatment by itself.

Interleukin-2, or IL-2, an immune therapy on the market since 1992 but rarely used, has had checkered success. Administered to a small, sturdy subset of patients by experienced treatment teams in high (and very toxic) doses, IL-2, also referred to as Proleukin, has the potential to provide a cure in a very small number of patients—5 to 10 percent—with advanced RCC. Researchers, however, are still trying to figure out exactly how it works. “Unfortunately, with decades of experience, we still do not understand why some people benefit tremendously and some don’t benefit at all,” Figlin says.

Sue Guenther, 60, of Mesa, Arizona, has experienced high-dose IL-2 firsthand as part of a clinical trial in 2006. “I call it flu in a bag. It makes you sick as a dog,” says Guenther, who is also a survivor of thyroid cancer and sarcoma.

Like many people with kidney cancer, her malignancy was discovered by happenstance—a misstep on some marble stairs, she says, literally saved her life. Guenther stepped down hard, and subsequent pain in her right kidney sent her to the doctor for scans.

That was in 2004, when she underwent a radical nephrectomy at Northwestern Memorial Hospital in Chicago for a large, stage 3 tumor near her liver. By early 2006, doctors found a 9-millimeter metastatic tumor in her lung, reduced to 2 millimeters after combination therapy, including IL-2, in the clinical trial.

Michael Atkins, MD, deputy director of the division of hematology-oncology at Beth Israel Deaconess Medical Center in Boston, believes high-dose IL-2 should remain an important first-line therapy because it is the only one shown to even occasionally cause complete and lasting responses—but it may be rendered less effective and more toxic after treatments such as Sutent. He acknowledges the issue is controversial.

“My view is there is a select group of patients and tumors, yet to be completely defined, that are best initially treated with IL-2, with the antiangiogenic or targeted agents reserved for those patients whose disease fails to respond to IL-2,” says Atkins, who is also leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and a professor of medicine at Harvard Medical School.

Although hard data are pending on factors that can predict responsiveness to IL-2, Atkins notes that researchers do have some idea of the clinical and biochemical characteristics that may mark patients most likely to benefit. The new therapies are a trade-off, he says. “While the new therapies help the average patient in a major way, without Proleukin, the cure of advanced kidney cancer is likely to become an even rarer event.”

Motzer, on the other hand, sees little role for IL-2, saying the current progress and excitement in the treatment of kidney cancer is based on the discovery and implementation of the targeted agents in the past five years.

The Ups and Downs

One disadvantage of the new drugs is a variety of toxic side effects. Another is price: They can cost tens of thousands of dollars a year. And the drugs require ongoing outpatient management, including monitoring for cardiovascular side effects in patients who received Sutent and/or Nexavar.

On Sutent, Benner had acid reflex, diarrhea, and fatigue, and had to drop his 50 mg daily dose to 37.5 mg. (Researchers are continuing to evaluate dosing strategies for the drug.) Everything, except chocolate, tasted like metal. On Nexavar, at an 800 mg daily dose, Benner developed a rash starting on his head and face, which moved to his chest and arms. “It almost was like second-degree burns,” he says, noting that his dose was reduced, then re-escalated. He takes special care of his feet, using ointments to avoid blisters that might arise from redness he has there. “I’m a pretty resilient person,” Benner says. “You can’t let a disease beat you.”

Guenther’s treatment odyssey, meanwhile, continued in 2007 and 2008, when she twice underwent cryoablation to treat tumors on her remaining kidney, which is functioning at about 70 percent. She, too, ended up on Sutent.

The first month, starting with a 50 mg daily dose that was later reduced to 37.5 mg, she found the fatigue devastating. The second month she also had a foul taste in her mouth and was living basically on just a few crackers a day. “I thought, ‘At least I’ll lose weight on Sutent,’ ” she says. But her doctor said no, people tend to gain weight on the drug. “It was then that I remembered God had a sense of humor.”

As of her last scans, her two major lung metastases were significantly reduced, and smaller lung spots were gone. “It looked like the Sutent was working,” she says. “This is living with cancer. But you’re living.”

Saturday, May 23, 2009

Cushing's and Adrenal Cancer:

Hope dies last

A 37-year-old father of two faces the dilemma of a rare cancerous disease

By Douglas Todd, Vancouver SunMay 23, 2009 at http://www.vancouversun.com/Health/Hope+dies+last/1623098/story.html

Max Rose and his wife, Stefanie WyerRose and their two sons, Cooper and Fisher, in their North Vancouver home.

Max Rose and his wife, Stefanie WyerRose and their two sons, Cooper and Fisher, in their North Vancouver home.

Photograph by: Ward Perrin, Vancouver Sun, Vancouver Sun

One of the hardest things for Max Rose to face is that he no longer has the strength to keep up with his two preschoolers, including carrying them up the stairs of the home he built in North Vancouver.

It's especially painful for the 37-year-old construction superintendent to deal with the fact one of his sons will soon be learning to ride a bicycle.

"I won't be able to run after him. That's going to be tough. I think of all the things I'd like to do with my sons, and hopefully I'll be able to. But still."

Max, who was supervising more than 100 trades workers on Vancouver's Olympic village project before he took medical leave late last year, is receiving intravenous chemotherapy for an extremely rare and virulent disease.

It's called adrenal cortical cancer.

Its rarity is part of what makes it so devastating. Since so few people are attacked by adrenal cancer, there has been virtually no research into targeted ways to treat it.

Adrenal cortical cancer strikes only one or two people per million. There are only about 600 patients throughout Canada and the U.S.

Adrenal cancer is considered an "orphan" disease because pharmaceutical companies calculate there is not enough money to be made researching drugs to combat it.

Still, U.S. Democratic Senator Edward Kennedy, who has brain cancer, is among the people leading legislative efforts that might address the dilemma of those battling rare and ultra-rare cancers.

The fight against the clock is on for Max and those who love him.

Last November, when doctors finally figured out why Max was suddenly gaining weight, feeling tired and bruising easily, his adrenal cancer was discovered to be stage four, the most serious stage.

Since the cancerous tumours were too advanced for surgery, he was told it would be unusual for him to live more than a year. His treatment is considered palliative.

Max was undergoing his third round of intravenous chemotherapy when I talked to him and his wife, Stefanie WyerRose, in the combined living- room/kitchen of their airy home.

"I'm trying to stay as positive as I can. I can do that or I can be negative and curl up in the fetal position and give up, which I'm not going to do," said Max, sitting on a couch with energetic Cooper, 2, and Fisher, 1, bustling nearby.

Members of Max's extended family, including his father Chris Rose, a former Vancouver Sun editor, are doing everything they can to improve his chances.

Max's wife of six years, who overcame her own bout of skin cancer almost five years ago, has been doggedly researching adrenal cancer and pressing for more research and better treatment regimens.

But Max and those who care about him are coming face-to- face with a major obstacle in the Canadian and international medical communities.

It relates to the ethics of triage.

That's the system of medical rationing that began on battlefields, where emergency doctors, nurses and resources were often in short supply.

Triage ethics developed with harsh simplicity: The soldiers considered most treatable were helped first. Those with the most grievous wounds were left until last, since their chances of survival were already poor.

Triage thinking continues to influence the apportioning of medical resources in North American society, where dollars are not infinite.

Sometimes it's called the ethics of scarcity.

Still, people like Stefanie are working hard for Max and others with adrenal and related rare cancers -- to raise their odds.

They have allies throughout the world. They also have ideas for reform.

RANDOM MISFORTUNE

There are so many difficult things about the life-and-death struggle Max and his family are enduring. Most are existential: the pure random misfortune of being struck with this unusual cancer of the adrenal endocrine glands, which are located above the kidneys.

Max's adrenal tumours were found last fall to have spread to his left liver and lungs.

Other difficulties relate to the medical system. For reasons related to the rarity of adrenal cancer, Max wasn't diagnosed early.

If medical personnel had discovered sooner that his symptoms, including Cushing's syndrome, were signalling something more serious, the cancer would have been more treatable.

When Max was interviewed in late March in his home in south Lonsdale, a cherry tree was blossoming in the yard. Corners of the shiny hardwood floors were covered with the toy trucks and diggers that, true to their dad's vocation, Max's sons like so much.

Max misses his career at Metro-Can Construction Ltd. He has supervised the building of Vancouver's Chan Centre for the Performing Arts, SkyTrain extensions and other high-profile projects.

"It's really hard not working. I worked with those guys for 15 years. I made longtime friendships."

The cheery brightness of the living room, and the innocent lack of awareness of the children, belied Max and Stefanie's inner struggles.

Despite his fatigue, Max was gracious, quick-witted and brave. And he and Stefanie had one bit of good news to pass on, the first in months.

A CT scan had shown that one of Max's adrenal gland tumours had shrunk by three centimetres. Another one, on his liver, may also have decreased.

The fairly standard cancer treatment Max has been receiving from his oncologist, Dr. Sasha Smiljanic, was having some effect. But the treatment is not particularly targeted to adrenal cancer, since the disease is not well understood.

Max's prognosis remains grim. "It's like somebody pulled a rug out from underneath your feet." To add to the extended family's plight, Max's stepfather has grave prostate cancer.

Stefanie, who works as a judicial assistant at B.C. Supreme Court, wears a purple "AC Warriors" bracelet to highlight the cause of adrenal cancer.

The family has been joined in the campaign to raise awareness for it and other rare diseases by two of the few British Columbians struggling with adrenal cancer.

Megan McNeil, 18, of North Delta, has recorded a song with Nickelback producer Garth Richardson to support cancer victims. It's titled, The Will to Survive. (Unlike Max, McNeil has been able to benefit from surgery.)

Another British Columbian with adrenal cancer, Victoria-based wildlife biologist Karen Truman, is raising money for the B.C. Cancer Agency, but said she's disappointed she's not allowed to divert the money to rare-cancer programs.

Both Max's family and Truman discovered on their own that a scientist at the University of Michigan, Dr. Gary Hammer, is one of the few experts on adrenal cancer in the world.

Truman, whose stage two adrenal cancer is not as advanced as Max's, paid out of her own pocket to fly to Michigan. Max paid to have his pathology report sent there.

Hammer, who is experimenting with genetically based treatments for adrenal cancer, provided the medical analysis that led to Max's current chemotherapy regimen, which he receives at Lions Gate Hospital.

Smiljanic, the oncologist who treats Max, says "there is a really heated debate" about whether rare-cancer patients like Max should receive travel costs to visit specialized treatment centres.

"In the policy area, the question is where do you draw the line?" said Smiljanic.

The B.C. Cancer Agency, said Smiljanic, has 40 to 50 oncologists treating patients with breast, colon and other common cancers with programs "that are the envy of other parts of the world."

But Canadians with rare cancers aren't in as strong a position as those with common cancers, in part because they "don't have a strong lobby group," said Smiljanic, who never had a patient with adrenal cancer until he met Max.

If Smiljanic was in Max's shoes, he'd consider enrolling in an experimental clinical trial for adrenal cancer, such as those at the University of Michigan. Max, however, would have to pay for his own travel and accommodation.

'A PRICE ON LIFE'

Simon Fraser University applied ethicist Mark Wexler has nothing but empathy for Max and his family.

They are doing their duty, he said, which is to do whatever they can to quickly get the best possible treatment.

However, Max is running into a wider ethical conflict: Even though our culture says every human life is "invaluable," society still places limits on how much to spend on an ailing individual.

"Some people ask, 'Isn't it hypocritical to admit we actually put a price on life?' " said Wexler.

But the hard reality is that society does put an economic value on a human life -- in a way reminiscent of so-called lifeboat ethics.

If there is only so much room in a lifeboat to save those who are drowning, if there is only so much money to help the sick, Wexler said society is forced to decide who is allowed on the lifeboat.

University of Victoria medical ethicist Eike Kluge agrees with Wexler that health care systems can't devote unlimited resources to people with rare cancers, while taking away from broader programs.

Kluge, who is being treated for prostate cancer, feels wholehearted sympathy for Max. Still, the professor of applied ethics said: "I often have to tell my students that not everything that is tragic is unethical."

Dr. Charles Blanke, who heads the B.C. Cancer Agency's systemic therapy program, said one of the hardest questions the organization has to face is how to fairly parcel out limited resources "so everybody gets at least a share of the pie."

Even though the B.C. Cancer Agency is covering Max's chemotherapy and will pay for out-of-province treatment, Blanke said the B.C. government won't pay for Max's travel and accommodation costs to attend clinical trials.

If Max isn't able to finance his own travel to specialized treatment programs, Blanke said Max could complete his chemotherapy treatment and then, depending on the outcome, seek a referral to the Vancouver Cancer Centre.

Some oncologists at the Vancouver Cancer Centre focus on rare cancers, Blanke said, and could, "on a case-by-case basis," try to provide targeted or even "highly experimental" treatment.

Still, the problem remains that adrenal cancers, unlike common cancers, don't have proven treatment programs.

LEVEL THE PLAYING FIELD

In a North American society that so strongly emphasizes economic gain, patients with rare diseases can be left behind, said the University of Michigan's Hammer.

In an effort to aid those with rare cancers, Hammer has been busily consulting with officials connected to the proposed Cancer Alert Act in the U.S.

The Alert Act is being brought before the House of Congress by Kennedy and Republican Senator Kay Hutchinson. It calls for increased funding for research and treatment of cancer, including rare and ultra-rare cancers.

It makes sense, Hammer said, that armies of researchers around the world are focusing on common cancers, like that of the breast and prostate. Breast cancer takes the lives of about 45,000 North Americans a year, while prostate cancer kills roughly 30,000.

"But it leaves other patients with rare cancers as orphans, with little hope for research into their diseases let alone treatment. How do you level the playing field somewhat?

"And how do you do that without breaking the bank? Our society and medical system shouldn't be based on only the survival of the fittest, on only social Darwinism."

Hammer has a series of arguments for increasing society's emphasis on rare cancers, which include those of the adrenal glands, saliva glands and tongue.

Hammer's first argument is that some of the most important advances in the field of cancer have been made studying rare cancers.

Discovering a targeted genetic-based therapy for adrenal cancer, which Hammer is working on through two clinical trials, could also help those with testicular and ovarian cancers.

Secondly, Hammer believes financial incentives could encourage research into uncommon diseases.

Government regulators, for instance, could approve rare-cancer drugs that are proven to shrink tumours even if they do not ensure long-term survival.

Pharmaceutical companies, he added, could also be given longer times to hold exclusive patents on drugs they discover to treat rare diseases.

Perhaps most importantly, Hammer calls for the establishment of rare-cancer "centres of excellence."

Since so few doctors in the world specialize in rare cancers, he thinks society's research and treatment efforts should be focused on leading international centres.

"Patients could be sent to wherever there is a centre of excellence. There could be reciprocal agreements between centres and even states and countries."

Some insurance companies have already financed sending adrenal-cancer patients to Hammer in Michigan. Other patients have paid out of their pockets.

Even though Dr. Smiljanic would support Max going to the University of Michigan, he cautioned it would not necessarily solve Max's rare-cancer dilemma. That's because taking part in clinical trials can be hit and miss.

It's possible, Smiljanic said, Max could end up, without his knowledge, in a "blind" control group that simply receives the "old treatment" for cancer -- not the targeted genetics-based treatments, which are themselves unproven.

Still, such clinical programs are important, at least for others.

"Sometimes the people who take part in clinical trials don't get to reap the benefits themselves," Smiljanic said. "But they will benefit someone in their situation in the future."

FIGHT FOR HIS LIFE

Despite the ethical, financial and political complexities around finding a targeted treatment for people with rare cancers, SFU ethicist Wexler is "totally supportive" of Max's family's efforts to fight for his life.

Families, Wexler said, operate by an unwritten code that says parents should die before their children. Max's loved ones, he said, are utterly justified in seeking help from whatever "deep pockets" they can, including government and private donors.

For his part, Max is not about to give up.

And he says he's not afraid. His attitude, and that of those around him, is reminiscent of the Russian proverb, "Hope is the last to die."

Max notes with a smile that doctors are surprised he has not lost his thick red hair from his chemotherapy treatments. "I tell them it's because I'm too stubborn."

Max also appreciates "the one good thing" to come with his excruciating diagnosis -- he's able to spend extra time with his sons.

Max knows what he's up against with his little-understood disease. He knows how medical rationing works. He's been told his chances.

But he's looking forward to a fishing trip this June near Merritt with his dad, stepbrother and father-in-law. And he's treasuring every moment with his family.

Everyone who cares about Max is yearning for him, and others like him.

They are realistic, but they will never stop hoping.

For many more springs.

Read Douglas Todd's blog at www.vancouversun.com/thesearch

© Copyright (c) The Vancouver Sun

Saturday, March 7, 2009

GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer

From http://www.pipelinereview.com/content/view/25590/109/

GlaxoSmithKline (GSK) today announced the submission of a Marketing Authorisation Application (MAA) tot he European Medicines Agency (EMEA) for pazopanib as an oral therapy for patients with advanced and/or metastatic renal cell carcinoma (RCC).

London, UK and Philadelphia, PA, USA | March 6, 2009 | GlaxoSmithKline (GSK) today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for pazopanib as an oral therapy for patients with advanced and/or metastatic renal cell carcinoma (RCC).

RCC is the most common type of kidney cancer.[1] The incidence of RCC is rising throughout the world[2] with 208,000 new cases diagnosed annually, and over 100,000 deaths.[3] More than 10 percent of new cases are diagnosed in Western Europe.[4]

Pazopanib is an investigational, oral, angiogenesis inhibitor which targets key proteins responsible for tumour growth and survival.[5]

The MAA submission is based on positive results from a randomised, double-blind, placebo-controlled Phase III study of pazopanib in treatment-naïve and cytokine-pre-treated patients with advanced RCC. The primary endpoint was progression-free survival. Secondary endpoints included overall survival, response rate and safety.[6] From previously published studies the most common side-effects associated with pazopanib treatment include diarrhoea, hypertension, hair colour change, nausea, anorexia and vomiting.5 The complete results from the Phase III study will be presented at an upcoming medical conference.

In December 2008, GSK also completed the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for pazopanib as an oral therapy for patients with advanced RCC. The filing is currently under regulatory review.

“If approved, pazopanib will offer physicians and patients a new therapeutic option for advanced kidney cancer and demonstrate our ongoing commitment to the development of innovative and personalised treatments for patients with cancer.” said Paolo Paoletti, Senior Vice President, R&D Oncology Unit.

“The MAA submission of pazopanib marks our fifth major submission since the formation of the R&D Oncology Unit in September 2008. Previous submissions included FDA filings for pazopanib and ofatumumab, and MAA submissions for ofatumumab and eltrombopag,” said Moncef Slaoui, Chairman, Research and Development. “These submissions underscore the value of a dedicated Oncology R&D Unit in capturing the many synergies that exist between discovery and development in oncology and in delivering more products of value.”

About Pazopanib

Pazopanib is an investigational, oral, once-daily angiogenesis inhibitor targeting VEGFR, PDGFR and c-kit.5 VEGF and PDGF are growth factors critical to the development and growth of blood vessels[7],[8] – a process known as angiogenesis.[9] Angiogenesis plays a pivotal role in the growth and spread of several tumour types, with VEGF and PDGF overexpression linked to multiple cancers.8,9

Within a broad clinical program across multiple tumour types, there are three Phase III studies currently underway. Pazopanib is also being evaluated as a monotherapy,in combination with targeted therapies and in combination with cytotoxic chemotherapy.More than 2,000 patients have been treated to date in clinical trials.

For further details please visit www.clinicaltrials.gov.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK’s revolutionary ‘bench to bedside’ approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centres. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com


SOURCE GlaxoSmithKline

Wednesday, December 31, 2008

Another Kidney Cancer Survivor!

MaryO'Note:  This article says: Rowell did not have to have chemotherapy or radiation for his tumors because such treatments are rarely effective for his type of cancer.

I'm so glad to see that they printed this.  When I tell people I didn't have chemo or radiation they think that means my cancer wasn't a serious one and they dismiss it.  It's nice to have this bit of validation!

From http://www.duncanbanner.com/local/local_story_365122658.html

Fighting the good fight

Pastor learns valuable lessons from battle with cancer

Jayne Boykin
The Duncan Banner

DUNCAN — Billy Rowell enjoys Christmas. In fact, the Duncan pastor enjoys every day of the year because it wasn’t too long ago that he thought those days might be coming to an end.

A self-employed carpenter and pastor of Grace Baptist Church, Rowell’s life was fairly routine, revolving around work, his church and family. He’s lived east of Duncan all his life, and graduated from Comanche High School in 1978. Rowell served as youth minister at the church for three or four years, as song leader for a year or two, then became its pastor almost two years ago, succeeding his father-in-law, the Rev. Bill Florez, who was pastor for many years.

Early in 2003, however, he began to have some “minor” health concerns. A trip to his doctor proved to be an eye-opener and the beginning of a long journey through the valley of the shadow of death to a new appreciation of life and a realization of the many blessings that life bestows.

“I was diagnosed with renal cell carcinoma — cancer — in my left kidney. That was a shock. I now know how people feel when they hear the ‘C-word.’ My kidney was removed in March of 2003 in Lawton, just before my 43rd birthday.

“My prognosis was good until July 2004. You know, when you have a serious illness like that, they watch you carefully. I had check-ups every three months, and PET scans, and they’d give me a good going-over. In July of that year, the tests showed two spots, lesions, I guess you’d call ’em, on my liver.”
A fairly new technique called radio frequency ablation literally “zapped” the liver spots away, and Rowell thought he was home free until his doctor walked into his hospital room.
“He said, ‘The liver is OK, but I found a tumor in your right kidney.’ I knew then that I was in trouble,” Rowell said.
Because Rowell had already lost one kidney, it was vital that his remaining kidney be saved, if at all possible. The tumor was removed but the kidney was severely damaged. What followed was a miserable year of bleeding, inability to work, pain, 23 times under anesthesia and four major surgeries.

“I have three scars over 14 inches long each on my gut. When they have to make an incision like that, they make the cut through all the muscles and stuff and then insert this huge stainless steel ring to stretch the opening and give them room to work. It takes a long time to recover from something like that,” he said.
During 2005, Rowell had at least one hospital stay every month except for April and May. The attempts to save his remaining kidney were making him really sick, he said.

“I learned then that Duncan is one of the greatest cities in the world. I love the people of Duncan. The whole community pitched in to support us with prayers and donations. One anonymous donor alone gave $16,000. Some oil field workers in Velma held a golf tournament and raised over $9,000. The outpouring was amazing.

“I’m so grateful for all the prayers. A man in Iowa learned about me on the Internet and put my name in a Catholic prayer chain that went to computers all over the world. Me, a Baptist preacher, and Catholics I never knew were praying for me. I’ve seen how God works, and it’s miraculous!”

Finally, his remaining kidney failed and had to be removed at OU Medical Center.

“My right kidney was the first known kidney to have been removed with radio frequency ablation. All of the surgery was done through a chest tube. A week and a half later, I was able to work again,” Rowell said.

Rowell did not have to have chemotherapy or radiation for his tumors because such treatments are rarely effective for his type of cancer.

“Not good enough odds,” he said.

“I’ve learned you had better enjoy every day you’ve got. Don’t take family or friends for granted. Life was OK before, now I love life. Faith got me through some difficult times. I feel blessed,” Rowell said.

Rowell credits his wife, Kim, with helping him get through the worst days. Kim Rowell is a human resources coordinator at Hydra-Rig. She stayed with her husband constantly during his hospitalizations, making sure he got the right medications and that his condition was carefully monitored as his disease progressed.

“She’s also got good medical insurance through her job. They don’t tell me what things cost. She and the insurance just take care of ’em.”

The couple has been married 30 years, and has two sons: Chris, 28, who lives in Blanchard, and Ryan, 26, who lives in Duncan. They also have a 19-month-old granddaughter, Brooklyn Grace, who is the apple of her grandfather’s eye.

Rowell went on kidney dialysis in March of 2005. He still takes the treatments that cleanse his body of toxins and fluids three days a week, along with about 30 pills a day. He continues his carpentry work on the days he’s not taking dialysis, and carries out his pastoral duties day and night, according to the needs of his congregation. He was ordained earlier this year.

Rowell said he’s learned some amazing things during the course of his illness.

“This body isn’t an accident. It’s too complicated not to have been made by God. It works good, too, until people mess it up,” he said.

Along with the support of his family and the overwhelming outpouring of help from the community, Rowell credits his recovery to staying positive and staying busy. While he’s taking his lengthy dialysis treatments, he talks with the people around him who are also taking treatments, and asks them how they’ve made it this far. The overwhelming response is “prayer and staying positive.”

“I want to last a while. I push myself and stay strong. You go downhill when you sit around,” he said.

“When you get a diagnosis of cancer, you’re going to have fear. You might act tough, but no matter what you do, you’re not dying until God says it’s time. Pain lets me know I’m alive. I look at things differently now.”

Rowell hopes to get on a kidney transplant list soon. He has to live nine more months cancer-free, then he can begin the lengthy testing process to get on a waiting list.

“I’m not sick. I don’t have kidney disease, I just have to depend on a machine to carry out the functions my missing kidneys would ordinarily do. I don’t feel normal, because of the poison levels in my body, but I choose to stay positive. I look forward to days. Worrying burns energy, takes away your life force. When things get to be too much for me, I just say, ‘God, you’re doing to have to deal with this.’ I don’t have to understand it all. I trust God and I know he has a wonderful place waiting for me, and that’s fine with me,” Rowell said.

Wednesday, December 24, 2008

UC Davis discovery offers hope for treating kidney cancer

KCRibbon From http://insciences.org/article.php?article_id=1030

Published on 23 December 2008, 11:25 by Insciences

Tags: Kidney cancer Cancer Cancer Biology Nephrology

(SACRAMENTO, Calif.) — Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.

In one of the first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for kidney cancer more effective and better tolerated. The outcome is published in the current issue of Cancer Biology and Therapy.
"Cancer cells are notorious in their ability to rapidly create copies of themselves. While the latest medications slow down that process, they do not tend to be curative and have many side effects," said Robert Weiss, a UC Davis professor of nephrology and chief of nephrology at the Sacramento VA Medical Center. "We wanted to find ways to help make chemotherapeutics as effective as possible at the lowest doses possible."

Newer medications work by destabilizing cancer cells at the DNA level, which reduces their ability to replicate. Knowing that the p21 gene has an important role in restoring cancer cell DNA and potentially circumventing the benefits of those treatments, Weiss sought to identify compounds that could interrupt this pathway.
The team tested thousands of compounds and 12 were found to bind to the recombinant protein p21. Additional tests showed that three of those compounds decreased p21 expression, blocking kidney cancer cells' ability to mend and making them more responsive to DNA-damaging treatments.

"The results are very exciting, especially given how difficult kidney cancer has so far been to treat," Weiss said. "Our work offers hope that in the future these p21 inhibitors can be refined and used in concert with other conventional as well as novel cancer treatments to increase the comfort and life spans of patients with kidney cancer."

For future studies, Weiss will focus on the three candidate compounds to determine the lowest possible concentrations at which they remain effective and to further optimize their anti-cancer properties. He will then test those compounds with standard treatments in animal models and, ultimately, in human trials.

"The goal is to find new approaches to treating a cancer for which few options currently exist and make those approaches available in clinical settings as quickly as possible," he said.

Other UC Davis study authors were See-Hyoung Park, Xiaobing Wang, Riuwu Liu and Kit Lam. Their research was supported by the National Cancer Institute, the U.S. Department of Veterans' Affairs, the Morris Animal Foundation, the National Institutes of Health and the National Science Foundation.

Designated by the National Cancer Institute, UC Davis Cancer Center's team of expert surgeons, medical oncologists and radiation therapists cooperate in the treatment of urological cancers. A strong research component drives the urologic cancer program, and active participation in national clinical trials gives our patients access to the newest treatment options. For more information, visit the cancer center Web site.

Tuesday, July 22, 2008

STF-62247: Molecule That Kills Kidney Cancer Cells

Sorry there's so much about kidney cancer right not and not as much about Cushing's but that's the way of the Google algorithm!

http://www.cancercommentary.com/2008/07/08/stf-62247-molecule-that-kills-kidney-cancer-cells/

STF-62247: Molecule That Kills Kidney Cancer Cells

A molecule called STF-62247 has been discovered by Stanford University School of Medicine researchers to be toxic against kidney cancer cells but is generally harmless to most other cells in the human body.

According to Amato Giaccia, PhD, professor and director of radiation oncology and radiation biology at the medical school:

“You now have a potential means of going after a disease that’s been difficult to treat. There is no effective chemotherapy to treat renal cell carcinoma. Patients still succumb. Clinical trials could begin “in the next couple years”.”

Above findings are published today in the journal Cancer Cell. Hopefully this discovery will in the future lessen the surgery option for kidney cancer treatment.

Read more from Science Daily.

Wednesday, July 2, 2008

Golden Oldies - Posts from the Past - Part 2

From November 17, 2006:

Catching Up With The Cancer

Since I had surgery for kidney cancer May 9, 2006, I've been looking around for somewhere to read and talk about this with other survivors (hopefully!) I haven't found anyplace I'd like to visit or feel comfortable with yet, so I decided to make a new blog here.

I'm sure that my recovery will be much the same as for any other major abdominal surgery, although I'd like it to be faster.

Before my surgery, I didn't have time really to consider that I had cancer, and what it meant for my life. There was no going from doctor to doctor, running a different test each week, suspecting that maybe... Just boom, there it is. Cancer.

Now that I'm about 6 months post-op, I'm thinking more and more about this and how it might affect my future. I know that there are going to be lots of scans, every 3 months, just to be sure that there wasn't a cell hiding out.

I know I have to be careful with meds - no NSAIDs so my arthritis is worse. I can no longer take hGH (recombinant growth hormone by daily injection, due to panhypopituitarism) even though I'm deficient. In 5 years (if I survive!) I can take the GH again, supposedly.

I'm supposed to be eating less protein, more fruits/veggies, drinking more water.

And I'm supposed to avoid playing football and other things that might damage my remaining kidney.

Normally, I know how very lucky I am. I just reread the path reports and know that the tumor was already hemorrhaging around the borders and the cysts contained hemorrhagic fluid. Things could be much worse.

Sometimes, at night when I can't sleep, I wonder why I was lucky like this. What haven't I done with my life that I should. Seems to me that I've accomplished what I should already.

And, in the night, I worry about the cancer returning, taking my other kidney or worse.

At this time, there's no standard chemo unless it's metastasized, although there are some promising clinical trials. Radiation doesn't seem to work for this kind of cancer, so if it returns it's more surgery.

From my past posts:

First off, I'd like to thank you all for your good wishes, support and prayers. I could do the Sally Field thing and say "...and I can't deny the fact that you like me, right now, you like me!" but I won't.

I plan to print everything out and take it with me to the hospital as a cheery-upper.

Alice has been such a wonderful friend through all this, calling, checking up on me, keeping all of you updated on things as they are known right now. Her support and love has been such a wonderful blessing in my life, especially now.

As it is, I'm currently feeling "normal" whatever that is. If I didn't know I had a problem, I would think that I was just fine.

I am fortunate that I found this out before the tumor could grow any larger. I am fortunate that I was close to the ER, not driving home from Baltimore, or in Baltimore, Oklahoma or on the cruise.

I know that the tumor has been growing for quite a while - it's very large. I saw the MRI images and even I can tell that it's not normal. As far as I know now, all the other scans have been fine. I had an abdomen CT, chest CT, brain MRI, chest/abdomen MRI and a full body bone scan.

When I was in the ER Friday, they assumed that it was a kidney stone and did the first abdominal CT scan looking to see where that was. They came back with the news that yes, I had a kidney stone but that it was the least of my worries at them moment. So, I was admitted to the hospital and had all the other scans except the bone scan. Knowing what I know now, it would have been better and easier for me to have had the bone scan as an inpatient. As soon as I checked out and was out of the system, it was harder to get an "emergency" (not scheduled weeks in advance) bone scan. Oh, well.

My surgery will be next Tuesday, May 9, at 9:30AM at Fairfax Hospital ( http://www.inova.org/inovapublic.srt/ifh/index.jsp ). I'm expected to stay there for 3-5 days post op and they don't anticipate any pesky complications like chemo or radiation at this time.

For now, I'm keeping my normal schedule, avoiding reading horror stories online, eating, sleeping - even napping! - as usual. Sometimes I even forget that I have this little medical appointment next week.

For a non-phone person I've talked with so many people these last few days, it's mind-boggling.

I'm happy to report that all is not lost on the cruise. Someone will replace me - and there will be another cruise later in the year. YEA! My main "concern" on that now is that I'll lose weight (finally!) post-op and my cruisewear will no longer fit. Yeah, right.

In thinking back, I think it's a good thing that my arginine test was messed up in Sept of 05. If it hadn't been, I wouldn't have redone it on Thursday. I believe that having that stuff in my body was what made my kidneys rebel and act up on Friday. So, without the lab screw-up I might not have known anything for a long time.

So, it's all good.

Thanks to everyone who has called and posted such wonderful things. I cannot begin to imagine what my email looks like...


and

June 12, 2006 post-op:

Thank you all for your prayers, good wishes, cards, phone calls, gifts, general "cheery-uppers". They all really helped me on my road to recovery.

I do have a ton of thank you cards to send out to lots of people - I'm very slow at that sad.gif Under normal circumstances my handwriting is terrible. Now, post-op kidney cancer, I can no longer take my arthritis meds or any NSAIDs and my writing will probably be even worse.

I am very nearly better, not much pain anymore, a nasty big scar and my energy levels aren't so great. Of course, they were awful before. I can no longer take the GH even though I'm deficient. In 5 years (if I survive!) I can take the GH again, supposedly.

I've had a lot of time to do a lot of thinking over the last 6 weeks. I know I was extraordinarily lucky to have my tumor discovered before it was too late. The lab reports and my surgeon reported that it would only have been a week or so before the tumor had hemorrhaged and caused major problems. Thank goodness the argenine retest for GH had caused me to bleed - at least I think that's what set it off. If I hadn't had all the blood and pain for one day only, I'd have had no clue that I had this cancer and who knows what would have happened in that next week.

I will be getting CT scans every 3 months for awhile to be sure that there is no cancer hiding out.


I plan to keep a kidney cancer journal of sorts in here, so years from now I can look back and laugh and wonder why in the world I was so worried.

I just updated my bio. I said:

Update October 26, 2006

I went to see my Johns Hopkins endo again last week. He doesn't "think" that my cancer was caused by the growth hormone although it may well have encouraged the tumor to grow faster than it would have.

He was happy to see that I had lost 22 pounds since my last 6 month visit. Not all of that was from surgery! He reminded me that I can take more cortisone, but I hate to do that because I gain weight so fast when I take more.

He thought that my blood pressure was low - for me, not for "normal" people. He took my pressure several times, lying down, getting up quickly. But I never got dizzy. Maybe my pressure increase was temporary when the cancer started. All these mysteries I have that no one can answer.

My energy levels are lower than when I was on GH, and they're lower again because I had the adrenal removed, because of my panhypopit, because of my cancer (even though currently NED, it can come back at any time, because of my GH deficiency...

Every day is a challenge getting up, doing something useful, doing something without arthritic pain and weakness, having the energy to finish even something "easy". I'm starting to get very depressed over all this.

If this is the way the rest of my life is going to be, why bother?


People mostly assume that everything is OK with me because I am not getting chemo or radiation and because I look so "healthy" (thanks to the Cushing's/daily Cortef!). They figure that if there was any real danger of the cancer metasticizing that I would be on chemo, like other cancer patients do.

They don't understand that I have to wait and pray because there are no approved ajuvant treatments. If/when my cancer returns, it's just more surgery. If I'm "lucky" enough and get to a stage 4 THEN I can have chemo/radiation as a pallative measure.

Aarrggh! Do I see starting a kidney cancer support group in my future?